 |
|
Serum and urine metabolomic biomarkers for predicting prognosis in patients with immunoglobulin A nephropathy
You Hyun Jeon, Sujin Lee, Da Woon Kim, Suhkmann Kim, Sun Sik Bae, Miyeun Han, Eun Young Seong, Sang Heon Song
Kidney Res Clin Pract. 2023;42(5):591-605. Published online 2023 May 18 DOI: https://doi.org/10.23876/j.krcp.22.146
|
|
Citations to this article as recorded by
 New biomarkers in IgA nephropathy
Zhixin Xu, Haoting Zhan, Jingdi Zhang, Zhan Li, Linlin Cheng, Qian Chen, Ye Guo, Yongzhe Li
Clinical Immunology.2025; 274: 110468. CrossRef Can we effectively manage chronic kidney disease with a precision-based pharmacotherapy plan? Where are we?
Francesco Locatelli, Ernesto Paoletti, Maura Ravera, Giulio Pucci Bella, Lucia Del Vecchio
Expert Opinion on Pharmacotherapy.2024; 25(9): 1145. CrossRef Omics Studies in CKD: Diagnostic Opportunities and Therapeutic Potential
Merita Rroji, Goce Spasovski
PROTEOMICS.2024;[Epub] CrossRef CKD Urine Metabolomics: Modern Concepts and Approaches
Elena Y. Danilova, Anna O. Maslova, Andrey N. Stavrianidi, Alexander E. Nosyrev, Larisa D. Maltseva, Olga L. Morozova
Pathophysiology.2023; 30(4): 443. CrossRef Metabolomics profiling: a potential tool for predicting immunoglobulin A nephropathy progression
Dong Ki Kim
Kidney Research and Clinical Practice.2023; 42(5): 539. CrossRef Virtual diagnosis of diabetic nephropathy using metabolomics in place of kidney biopsy: The DIAMOND study
Da Woon Kim, Hyo Jin Kim, Eun Young Seong, Sang Soo Kim, Sujin Lee, Suhkmann Kim, Chae Hwa Kwon, Sang Heon Song
Diabetes Research and Clinical Practice.2023; 205: 110986. CrossRef
|